16208-51-8
Chemical Structure
Dimesna
Synonym(s): BNP-7787
- CAS No.: 16208-51-8
- Formula:C4H8Na2O6S4
- Molecular Weight:326.34
IUPAC Name: sodium 2,2'-disulfanediylbis(ethane-1-sulfonate)
InChIKey: KQYGMURBTJPBPQ-UHFFFAOYSA-L
SMILES: O=S(CCSSCCS(=O)(O[Na])=O)(O[Na])=O
Biological Activity: Dimesna (BNP-7787), the disulfide form of Mesna (HY-13679), is a platinum-related toxicity protective agent. Dimesna converts to Mesna, which in turn inactivates toxic platinum substances. Dimesna does not interfere with the antitumor activity of platinum compounds. Dimesna does not affect the antiproliferative effects of Cisplatin (HY-17394) or Carboplatin (HY-17393). Dimesna counteracts Cisplatin-induced nephrotoxicity. Dimesna exerts selective protective effects on the kidneys. Dimesna can be used in studies related to ovarian cancer and Cisplatin-induced nephrotoxicity[2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dimesna | 98.0% | Dimesna (BNP-7787), the disulfide form of Mesna (HY-13679), is a platinum-related toxicity protective agent. Dimesna converts to Mesna, which in turn inactivates toxic platinum substances. Dimesna does not interfere with the antitumor activity of platinum compounds. Dimesna does not affect the antiproliferative effects of Cisplatin (HY-17394) or Carboplatin (HY-17393). Dimesna counteracts Cisplatin-induced nephrotoxicity. Dimesna exerts selective protective effects on the kidneys. Dimesna can be used in studies related to ovarian cancer and Cisplatin-induced nephrotoxicity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dimesna-d8 | Dimesna-d8 (BNP-7787-d8) is the deuterium labeled Dimesna (HY-B1022). Dimesna combined with anticancer chemotherapeutic agents to reduce nephrotoxicity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [2]. Boven E, et al. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer. 2002;38(8):1148-1156. [Content Brief]
- [3]. Verschraagen M, et al. Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats. Br J Cancer. 2004;90(8):1654-1659. [Content Brief]
Keywords
